 sell
- There is no classification
contact
- Contact：德里健康
- Phone：4008087091
link |
|
The 2015 Hepatitis C Management Guidelines declared that Hepatitis C can be cured, bringing great hope to Hepatitis C patients. Trr requires the use of interferon combined with ribavirin. Due to severe side effects, it has been removed from the US hepatitis C treatment guidelines in 2018. Also eliminated was the d plus ribavirin regimen.
Gilead's second generation is a compound preparation, and its active ingredients are rg + dr g. The ingredients of India's second generation of Gilead are exactly the same as those of the H product produced by Gilead in the United States. Based on the second generation treatment of Hepatitis C, it does not need to be combined with interferon, is simple to take, and has a high cure rate (above %). It is currently the most ideal drug treatment plan for patients with Hepatitis C and Hepatitis C. In addition, daclatasvir (Dtr) products produced by Indian pharmaceutical companies have also been launched on the market. The treatment plan based on sofosbuvir (r) + daclatasvir (Dtr) (also known as the EU plan) is currently the most ideal plan for clinical hepatitis C patients.
Hepatitis C patients are both unfortunate and lucky. Fortunately, the patients have waited until the second generation of Gilead is launched. Some patients have obtained the new drug through various channels, and the results are very good, with seven days of TD and normal liver function. But it will take some time for new drugs to enter the Chinese market.
In order to allow the majority of hepatitis C patients to use new drugs in a timely manner, afford them, and take them with confidence, Delhi Health has become the designated partner of India's Apollo Hospital and Fortis Hospital in China after many contacts and efforts. Chinese patients can purchase various Indian medicines directly from Apollo Hospitals and Fortis Hospitals through telemedicine services without leaving home. The purchased medicines are delivered directly to the patients through international express delivery by Apollo Hospitals and Fortis Hospitals. |
| Company Name： |
Hebei Delhi Health Management Service Co., Ltd. |
Company type： |
企业单位 (贸易商,服务商) |
| location： |
Hebei/Shijiazhuang City |
Company Size： |
1-49人 |
| Registered capital： |
2000M人民币 |
Registration year： |
2016 |
| Data certification： |
 |
| Security deposit： |
Already paid 0.00 元 |
| Operation model： |
贸易商,服务商 |
| Business Scope： |
health medical services |
| major business： |
|
|
